Key clinical point: Expanded noninvasive prenatal testing (NIPT-plus) is better at predicting fetal chromosome abnormalities in pregnant women of advanced maternal age (AMA) than in those of young maternal age (YMA).
Main finding: The positive predictive value of NIPT-plus in AMA pregnancies vs. YMA pregnancies was 57.6% vs. 35.7% ( P < .05) for sex chromosome aneuploidies (SCA) and 77.8% vs. 51.9% ( P < .05) for chromosome aneuploidies, including trisomies 21, 18, and 13, and SCAs.
Study details: The data come from a retrospective cohort study including 448 pregnant women with screen-positive results by NIPT-plus for fetal chromosome abnormality in the second trimester, who underwent prenatal diagnosis, of which 27% were AMA pregnancies.
Disclosures: The study was funded by the National Nature Science Foundation of China. None of the authors reported having a conflicts of interests.
Source: Chen Y et al. Am J Med Genet A. 2022 (Feb 2). Doi: 10.1002/ajmg.a.62657.